Clinical trials
Germline Mutations clinical trials
Below are recruiting germline mutations clinical trials, each written for real people, not researchers. We’re tracking 25 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+ - NCT01994057Recruiting
Looking back at EGFR-targeted pills for lung cancer
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
Guangzhou, GuangdongAges 18–85 - NCT07436312Recruiting
Effect of ultra-processed foods on cancer risk in high-risk people
This trial looks at whether eating less ultra-processed foods can lower cancer risk in people who are already at high risk for cancer. It is part of a larger program called Interception that helps monitor and reduce cancer risk.
AvignonAges 18 years+ - NCT02000089RecruitingPhase 3
Pancreas screening study for people at high cancer risk
This Phase 3 study tests a structured plan for checking the pancreas early in people with a higher-than-usual risk of pancreatic cancer. The goal is to find changes sooner, when treatment may be easier.
New Haven, ConnecticutAges 18 years+ - NCT06917794Enrolling by invitation
Genetic risk study for colon cancer patients
This study looks at how your genetic background and ancestry affect your risk for colon cancer. If you have been diagnosed with colon cancer and have a tumor sample available, you may be able to help researchers develop better risk scores.
Fortaleza, CearáAges 18 years+ - NCT05983991Recruiting
Study of GATA2 gene changes over time
This study looks at how GATA2 gene changes affect your blood cells over time. It is for people of any age who have a GATA2 mutation they were born with, and it does not test a new drug—just collects information and samples during regular checkups.
AngersAges Any age - NCT07419893Recruiting
Study of TP53 gene test results
This study looks at results from people who have already had TP53 gene testing through IEO’s genetics clinic. It helps doctors learn more about how this gene relates to cancer risk.
MilanAges 18–90 - NCT07292246Recruiting
HandX-assisted endoscopic mastectomy study for breast cancer
This trial tests a new, less invasive way to remove breast tissue using a small camera (endoscope) with a device called HandX. It's for women who need a mastectomy for early-stage breast cancer, DCIS, or to reduce high risk, and aims to see if it's safe and works well.
Glyfada, AtticaAges 18 years+ - NCT07204392Recruiting
Genetic study for early-onset or familial MPN
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
Pavia, LombardyAges 18 years+ - NCT07556562Recruiting
Early ovarian cancer detection through Pap test DNA analysis
This study tests whether DNA found in routine Pap smears can help detect ovarian cancer early in people at high genetic risk. Participants have inherited gene mutations that increase ovarian cancer risk and are considering preventive surgery.
Roma, RomaAges 18 years+ - NCT03830229Recruiting
Long-term follow-up for people with BAP1 mutations
This study follows people with a harmful (deleterious) BAP1 gene change to learn how it affects health over time. It may help researchers better understand mesothelioma risk and the long-term outcomes for families with this genetic mutation.
Bethesda, MarylandAges 2 years+ - NCT04995198Recruiting
Prostate cancer patient registry for genetics and treatment outcomes
This registry collects information from people with prostate cancer to better understand how genetics and treatments affect survival and outcomes. Your data may help researchers improve future treatment choices.
Baltimore, MarylandAges 18 years+ - NCT05072483Recruiting
Study of CADASIL’s natural course using blood tests and MRI
This study follows people with CADASIL (a genetic brain blood-vessel condition) to learn how it progresses over time. It uses blood and possibly tissue samples and brain MRI scans to better understand changes in the brain.
Bethesda, MarylandAges 18–100 - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT07019155Recruiting
DDX41 gene study for families with cancer risk
This study looks at people and families who have changes in the DDX41 gene or similar genes that may increase the risk of cancer. By joining, you can help researchers learn more about these gene changes and how they affect health.
Bethesda, MarylandAges 1 month–120 years - NCT02705846Recruiting
Study tracks outcomes in men with inherited prostate cancer risks
This study looks at how prostate cancer diagnoses and treatments turn out over time. It compares men who carry rare inherited gene changes that raise prostate cancer risk with men who do not, to better understand which treatments and outcomes may differ.
Sutton, SurreyAges 18 years+ - NCT05420779RecruitingPhase 2
TSL-1502 for breast cancer with BRCA gene mutations
This Phase 2 trial tests TSL-1502 capsules, a targeted medicine for breast cancer, in people whose blood test shows a harmful BRCA gene mutation. It aims to see whether it can control the cancer and how safe it is after prior treatment.
BeijingAges 18–75 - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT07069335RecruitingPhase 1
Studying a new form of olaparib for BRCA-mutated ovarian cancer
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Seoul, Songpa DistrictAges 19–74 - NCT02302742Recruiting
Registry for triple-negative breast cancer and inherited mutation carriers
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Hays, KansasAges Any age - NCT05769517Recruiting
Using ultrasound to predict BRCA genes from healthy ovaries
This study looks at whether pictures from a vaginal (transvaginal) ultrasound of a healthy ovary can help predict whether someone carries BRCA1 or BRCA2 gene changes. It may help identify people who could benefit from more genetic testing, without needing new ultrasound images.
RomeAges Any age
Hear when a new Germline Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for germline mutations?
- Yes. Clin2 currently lists 25 recruiting germline mutations studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a germline mutations trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a germline mutations trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.